October 1, 2004Journal of Cardiovascular Pharmacology and Therapeutics
Intravenous Nitroglycerin in the Treatment of Decompensated Heart Failure: Potential Benefits and Limitations
Why the study?
Does intravenous nitroglycerin improve hemodynamic effects and symptoms in patients with acute decompensated heart failure?
Population
Patients with acute decompensated heart failure (ADHF)
Comparison
Intravenous nitroglycerin vs Placebo
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Questions routine intravenous nitroglycerin use in acute decompensated heart failure; leaves open tolerance-mitigating or higher-dose strategies.
Structured PICO
Does intravenous nitroglycerin improve hemodynamic effects and symptoms in patients with acute decompensated heart failure?
P
Population
Patients with acute decompensated heart failure (ADHF)
I
Intervention
Intravenous nitroglycerin
C
Comparator
Placebo
O
Outcome
Hemodynamic effects and improvement of symptoms
Despite widespread use, intravenous nitroglycerin for acute decompensated heart failure lacks robust cardiovascular outcome data and its efficacy is limited by nitrate tolerance and the need for high doses.
Limitations
- Information is limited to mostly hemodynamic evaluations in small groups of patients
- Lack of cardiovascular outcome data
Cite This Study
Elkayam et al. (2004) studied this question.